---
title: "SSY Group Wins Key China Drug Approvals, Expands Chronic and Pediatric Portfolio"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285308388.md"
description: "SSY Group has received key approvals in China, becoming the first to secure production and registration for a fat-soluble vitamin injection for infants. The company also gained regulatory approvals for metformin hydrochloride tablets and doxazosin mesylate extended release tablets, enhancing its chronic disease portfolio. These developments position SSY Group competitively in the generic drug market. Analysts rate the stock as a Buy with a target price of HK$5.00. SSY Group focuses on developing injectable and oral medications in pediatrics and chronic disease management."
datetime: "2026-05-06T04:07:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285308388.md)
  - [en](https://longbridge.com/en/news/285308388.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285308388.md)
---

# SSY Group Wins Key China Drug Approvals, Expands Chronic and Pediatric Portfolio

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

SSY Group ( (HK:2005) ) has issued an update.

SSY Group has strengthened its pediatric portfolio by becoming the first Chinese entity to secure production and registration approval for a fat-soluble vitamin injection for infants and children, covering vitamins A, D2, E and K1 via intravenous infusion. This move underscores the company’s push into specialized nutritional therapies and enhances its differentiation in the hospital injection market.

The group also obtained Chinese regulatory approvals for metformin hydrochloride tablets for type 2 diabetes and doxazosin mesylate extended release tablets for benign prostatic hyperplasia and hypertension, all passing consistency evaluation standards. These new approvals, alongside its previously cleared doxazosin bulk drug, broaden SSY’s chronic disease offerings and support its competitiveness in China’s increasingly quality-focused generic drug landscape.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

**More about SSY Group**

SSY Group Limited is a China-based pharmaceutical company focused on developing and manufacturing injectable and oral medications. The group targets key therapeutic areas such as pediatrics, endocrinology and chronic disease management, supplying both finished dosage forms and bulk drugs to the domestic healthcare market.

**Average Trading Volume:** 9,836,963

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$6.76B

Find detailed analytics on 2005 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [02005.HK](https://longbridge.com/en/quote/02005.HK.md)

## Related News & Research

- [SSY Group Wins Trio of NMPA Approvals, Expanding China Drug Portfolio](https://longbridge.com/en/news/285859735.md)
- [SSY Group Profit Halves as Revenue and Margins Slide in Challenging 2025](https://longbridge.com/en/news/280725971.md)
- [AIA Singapore targets 90% of illness claims](https://longbridge.com/en/news/287132135.md)
- [20:00 ETAccro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases](https://longbridge.com/en/news/286830151.md)
- [09:03 ETOrthoArizona Expands Pinnacle Pain with New Chandler Facility and New Physician](https://longbridge.com/en/news/287070954.md)